http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180030302-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c63cd52dd9511a65ad4925da0df385d |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-01 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-66 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
filingDate | 2016-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_915f4169c5b912a1b2ed899062ccd694 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c725509b529e22d1adce3f3bfb6a2b5f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48984624224f25d2ffe2e820e3c4ab79 |
publicationDate | 2018-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-20180030302-A |
titleOfInvention | Novel cell membrane penetrating peptide derived from alpha-synuclein |
abstract | The present invention relates to a novel cell membrane permeable peptide or a mutant thereof derived from a-synuclein, which does not exhibit cytotoxicity and shows cell membrane permeability in an energy-dependent manner, a polynucleotide encoding the cell membrane permeable peptide or a variant thereof, A transformant into which the expression vector is introduced, and a complex in which the desired drug is bound to the cell membrane permeable peptide or a variant thereof, to a composition for intracellular drug delivery. The cell membrane permeable peptide or its variant of the present invention exhibits cell membrane permeability to various cells without exhibiting cytotoxicity, and thus it can be widely used in the development of drugs for cell drug delivery. |
priorityDate | 2016-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 102.